查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677253

重組尿酸酶市場按產品類型、給藥途徑、應用和最終用戶分類 - 2025 年至 2030 年全球預測

Recombinant Uricase Market by Product Type, Route Of Administration, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

重組尿酸酶市場規模預計在 2024 年達到 14.4 億美元，在 2025 年達到 15.3 億美元，年複合成長率為 5.94%，到 2030 年達到 20.4 億美元。

主要市場統計數據
基準年 2024 年 14.4億美元
預計 2025 年 15.3億美元
預測年份 2030 20.4億美元
複合年成長率（%） 5.94％

重組尿酸酶市場處於尖端生物技術創新和大量臨床需求的交匯處。在本報告中，我們介紹了重組尿酸酶的複雜概況，並探討了其在治療性介入介入中的變革作用。生物製藥的快速發展和基因工程的進步正在擴大重組尿酸酶的潛在應用。該市場專注於尿酸水平異常突出的情況，包括某些腎臟和代謝疾病，為性能、安全性和改善患者結果提供關鍵見解。此外，新興的臨床資料和正在進行的研究正在重新定義重組尿酸酶超越傳統治療方法的價值提案。本介紹分析建立了一個框架來理解酵素療法的細微差別，同時深入探討市場促進因素、監管挑戰和科學突破的影響。該報告旨在為行業專業人士和決策者提供服務，深入了解當前市場表現以及未來市場發展，以及在競爭日益激烈的全球醫療保健領域改善治療結果的途徑。

改變重組尿酸酶市場

過去幾年中，在科學快速進步和產業模式不斷發展的推動下，重組尿酸酶市場發生了動態變化。分子工程和製程最佳化的重大進展促使從傳統酵素療法轉向新型生物製藥製劑的轉變。最近，聚乙二醇化技術和非聚乙二醇化製劑的改進重新定義了這些治療酵素的耐受性和藥物動力學特徵。此外，監管部門的核准和監督力度的加強使得臨床試驗的方法更加標準化，以確保新配方的有效性和安全性。此外，數位監控系統和以患者為中心的資料收集的整合使得治療通訊協定的調整更加精確，從而增強了市場信心。這種演變並不是孤立的現象，而是代表了全球邁向個人化醫療的一致步伐。投資者和臨床研究人員越來越關注先進生物加工、產品差異化和改善醫療保健之間的相互作用。總的來說，這些發展建立了一個強大的框架，以促進新產品創新，最佳化供應鏈效率，並開創科學與商業之間更複雜的相互關係時代。預計此類轉變將重塑市場策略，並在未來幾年推動與競爭對手的差異化。

重組尿酸酶市場的關鍵細分見解

重組尿酸酶市場的詳細細分描繪出一個多方面的故事，其中融合了特定產品和特定應用的策略以及地理和最終用戶的考慮。按產品類型進行的評估重點是重組尿酸酶、非聚乙二醇化尿酸酶和聚乙二醇化尿酸酶生物學名藥，每種產品都表現出獨特的特性和臨床益處，與治療領域的目標群體產生共鳴。給藥途徑增加了進一步的見解，臨床結果顯示肌肉注射、靜脈注射和皮下注射系統之間存在差異。根據應用，市場對癌症治療、腎臟病學、神經系統疾病和罕見遺傳疾病等不同治療領域進行了廣泛的分析。該報告提供了痛風治療的詳細觀點，強調了慢性痛風、高尿酸血症、難治性痛風和腫瘤崩壞症候群等子類別，說明了不斷變化的臨床需求。此外，基於最終用戶的細分探討了醫療保健提供者、製藥商和研發組織如何利用這些創新來推動採用並最佳化以患者為中心的護理。醫療保健提供者部門對診所、透析中心和醫院進行了深入分析，強調了利用模式和治療結果的差異。這種市場區隔洞察不僅凸顯了影響市場動態的多因素考慮，而且還透過微調對目標群體及其個人需求的理解來實現更好的策略規劃和合理的產品定位。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球痛風和高尿酸血症盛行率不斷上升
      • 提高對標靶治療和個人化醫療方法的認知
      • 不斷擴大的患者群體、新的藥物治療方案和支持性法規結構
    • 限制因素
      • 重組尿酸酵素治療高成本
    • 機會
      • 開發具有更高功效和安全性的新型尿酸酶治療方法
      • 加強監管獎勵，包括孤兒藥指定，以鼓勵創新
    • 任務
      • 可能的副作用和抗藥性抗體的產生
  • 市場區隔分析
    • 產品類型：在需要快速管理複雜性痛風和高尿酸血症的急性照護環境中，非聚乙二醇化尿酸酶是首選。
    • 用途：對控制高尿酸水平的實用解決方案的持續需求導致了痛風治療的廣泛採用。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境

6. 重組尿酸酶市場（依產品類型）

  • 重組尿酸酶的生物相似藥
  • 非聚乙二醇化尿酸酶
  • 聚乙二醇化尿酸酶

7. 重組尿酸酶市場依給藥途徑分類

  • 肌肉注射
  • 靜脈
  • 皮下

8. 重組尿酸酶市場（依應用）

  • 癌症治療
  • 痛風治療
    • 慢性痛風
    • 高尿酸血症
    • 難治性痛風
    • 腫瘤崩壞症候群
  • 腎臟疾病
  • 神經系統疾病
  • 罕見遺傳疾病

9. 重組尿酸酶市場（依最終用戶分類）

  • 醫療保健提供者
    • 診所
    • 透析中心
    • 醫院
  • 製藥商
  • 研究開發研究所

10. 美洲重組尿酸酶市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太地區重組尿酸酶市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲重組尿酸酶市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • 3SBio Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Biosynth Ltd
  • Creative Enzymes
  • CUSABIO TECHNOLOGY LLC
  • GenScript Biotech Corporation
  • Hzymes Biotech
  • Innovent Biologics, Inc.
  • Kikkoman Corporation
  • Merck KGaA
  • OYC Americas, Inc.
  • Protalix BioTherapeutics
  • Sisco Research Laboratories Pvt. Ltd.
  • Swedish Orphan Biovitrum AB
Product Code: MRR-094390F400F7

The Recombinant Uricase Market was valued at USD 1.44 billion in 2024 and is projected to grow to USD 1.53 billion in 2025, with a CAGR of 5.94%, reaching USD 2.04 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.44 billion
Estimated Year [2025] USD 1.53 billion
Forecast Year [2030] USD 2.04 billion
CAGR (%) 5.94%

The recombinant uricase market stands at the confluence of cutting-edge biotechnology innovation and significant clinical demand. This report introduces the intricate landscape of recombinant uricase, exploring its transformative role in therapeutic interventions. The rapid evolution in biopharmaceuticals, paired with advances in genetic engineering, has expanded the potential for recombinant uricase applications. With a focus on conditions marked by aberrant uric acid levels, such as certain renal and metabolic disorders, this market offers crucial insights into performance, safety, and improved patient outcomes. Furthermore, emerging clinical data and ongoing research are redefining the value proposition of recombinant uricase beyond traditional treatments. This introductory analysis establishes a framework for understanding the nuances of enzymatic therapy, while taking a deep dive into market drivers, regulatory challenges, and the implications of scientific breakthroughs. The report is structured to serve industry professionals and decision-makers by demonstrating not just current market performance, but also pathways for future development and enhanced therapeutic efficacy in an increasingly competitive global health arena.

Transformative Shifts in the Recombinant Uricase Landscape

Over the past few years, the recombinant uricase market has experienced dynamic shifts propelled by rapid scientific advancement and evolving industry paradigms. Significant progress in molecular engineering and process optimization has driven the transition from conventional enzyme therapies to novel biopharmaceutical formulations. In recent times, improvements in pegylation techniques and non-pegylated formulations have redefined the tolerability and pharmacokinetic profiles of these therapeutic enzymes. Regulatory approvals and heightened scrutiny have also catalyzed a more standardized approach to clinical trials, ensuring that novel formulations are both efficacious and safe. Furthermore, integration of digital monitoring systems and patient-centric data collection has enabled more precise adjustments in therapy protocols, thereby bolstering market confidence. These evolutionary shifts are not isolated phenomena; rather, they represent a concerted global movement toward personalized medicine. Investors and clinical researchers are increasingly focusing on the interplay of advanced bioprocessing, product differentiation, and improved healthcare delivery methods. Collectively, these developments have established a robust framework that inspires new product innovation, optimizes supply chain efficiencies, and ushers in an era where science and commerce are more intricately connected. Such shifts are expected to realign market strategies and drive competitive differentiation in the coming years.

Key Segmentation Insights in the Recombinant Uricase Market

In-depth segmentation of the recombinant uricase market reveals a multifaceted narrative that integrates both product and application specific strategies alongside regional and end-user considerations. When evaluated on the basis of product type, the study zeroes in on biosimilars of recombinant uricase, non-pegylated uricase, and pegylated uricase, each displaying unique properties and clinical benefits that resonate with targeted segments in the therapeutic arena. The route of administration further refines these insights, documenting variations in clinical outcomes between intramuscular, intravenous, and subcutaneous delivery systems. In terms of application, the market is expansively analyzed across diverse therapeutic areas including cancer treatment, kidney diseases, neurological disorders, and rare genetic disorders. A closer examination of gout treatment provides a granular perspective, shedding light on chronic gout, hyperuricemia, refractory gout, and tumor lysis syndrome subcategories that indicate evolving clinical demands. Additionally, the segmentation based on end-users examines how healthcare providers, pharmaceutical manufacturers, and research and development institutes leverage these innovations to drive adoption and optimize patient-centric care. Within the healthcare provider segment, clinics, dialysis centers, and hospitals are analyzed in detail to highlight differential utilization patterns and therapeutic outcomes. These segmentation insights not only underscore the multifactorial considerations that shape market dynamics but also fine-tune the understanding of target groups and their individual needs, thereby enabling more precise strategic planning and streamlined product positioning.

Based on Product Type, market is studied across Biosimilars of Recombinant Uricase, Non-Pegylated Uricase, and Pegylated Uricase.

Based on Route Of Administration, market is studied across Intramuscular, Intravenous, and Subcutaneous.

Based on Application, market is studied across Cancer Treatment, Gout Treatment, Kidney Diseases, Neurological Disorders, and Rare Genetic Disorders. The Gout Treatment is further studied across Chronic Gout, Hyperuricemia, Refractory Gout, and Tumor Lysis Syndrome.

Based on End-User, market is studied across Healthcare Providers, Pharmaceutical Manufacturers, and Research & Development Institutes. The Healthcare Providers is further studied across Clinics, Dialysis Centers, and Hospitals.

Regional Perspectives on the Recombinant Uricase Market

A comprehensive regional analysis brings to light distinct opportunities and operational challenges across key geographic territories. In the Americas, robust economic growth coupled with advanced healthcare infrastructures has led to significant demand for novel therapeutic agents, with recombinant uricase steadily gaining traction in clinical protocols. In contrast, the Europe, Middle East & Africa region presents a diverse portfolio of regulatory frameworks and financing mechanisms. Here, mature healthcare markets are leveraging established research networks and robust logistics to foster innovation and deliver tailored healthcare solutions. Meanwhile, the Asia-Pacific region has emerged as a rapidly expanding market driven by rising healthcare expenditures, expansive patient pools, and substantial governmental support for biotechnology research. Each region presents its own unique set of challenges and advantages, ranging from regulatory simplification and cross-border collaboration to competitive pricing strategies and high adoption rates in emerging economies. The intricate interplay between political stability, fiscal policies, and localized regulatory frameworks across these regions propels market growth, while the evolving consumer demand in each territory emphasizes the need for agile strategies and region-specific market entry tactics. This analysis brings forth key regional insights that are critical for stakeholders to navigate the differing market landscapes efficiently and capitalize on the inherent opportunities.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Key Market Players in the Recombinant Uricase Field

The competitive landscape of the recombinant uricase market is marked by the presence of a diverse array of companies that are continuously driving industry advancements and innovation. Companies such as 3SBio Inc. and BioCryst Pharmaceuticals, Inc. have distinguished themselves through a strong track record in enzyme research and clinical trial execution. Firms like Biosynth Ltd and Creative Enzymes are recognized for their strategic investments in bioprocessing technologies, which have enhanced product scalability and quality control. The market further benefits from the contributions of organizations such as CUSABIO TECHNOLOGY LLC and GenScript Biotech Corporation, which have excelled in offering customized solutions that enhance the flexibility and precision of recombinant uricase formulations. Market leaders including Hzymes Biotech and Innovent Biologics, Inc. have ushered in groundbreaking advancements through innovative drug delivery mechanisms and improved bioconjugation processes. Additionally, prominent industry players such as Kikkoman Corporation, Merck KGaA, and OYC Americas, Inc. have operationalized extensive research networks and leveraged global supply chains to sustain their competitive edge. Protalix BioTherapeutics, Sisco Research Laboratories Pvt. Ltd., and Swedish Orphan Biovitrum AB also contribute significantly by integrating research excellence with robust manufacturing capabilities. These key companies collectively stimulate innovation, shape regulatory standards, and drive market dynamics that benefit a broader spectrum of stakeholders. Their strategic initiatives not only foster competitive differentiation but also serve as pivotal drivers in reducing time-to-market for next-generation formulations.

The report delves into recent significant developments in the Recombinant Uricase Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., BioCryst Pharmaceuticals, Inc., Biosynth Ltd, Creative Enzymes, CUSABIO TECHNOLOGY LLC, GenScript Biotech Corporation, Hzymes Biotech, Innovent Biologics, Inc., Kikkoman Corporation, Merck KGaA, OYC Americas, Inc., Protalix BioTherapeutics, Sisco Research Laboratories Pvt. Ltd., and Swedish Orphan Biovitrum AB. Actionable Recommendations for Industry Leaders in Recombinant Uricase

Industry leaders are encouraged to harness the momentum of current market dynamics by adopting targeted strategies that align with emerging technological trends and patient-centric demands. It is imperative to invest in research and development to refine existing formulations and explore innovative delivery platforms that can enhance therapeutic efficacy and patient adherence. Organizations should prioritize collaborations with clinical research institutes to validate novel hypotheses and accelerate the translation of cutting-edge discoveries into viable products. In addition, the integration of digital tools and real-time data analytics can empower decision-makers with deeper insights into market behavior and patient outcomes. Strengthening supply chain optimization and adopting agile manufacturing frameworks can further mitigate risks associated with regulatory complexities and market volatility. Simultaneously, fostering strong partnerships across the healthcare continuum-from academic research to hospital networks-ensures that insights gleaned from clinical practice are seamlessly integrated into product development processes. Strategic market segmentation and targeted marketing campaigns can significantly enhance brand recall and customer engagement among key stakeholders. Leaders are also advised to leverage regulatory incentives and seek collaborative platforms for knowledge exchange, thus positioning themselves at the forefront of industry innovation. By marrying technological advancements with strategic foresight, industry stakeholders can create a sustainable competitive advantage while addressing unmet clinical needs.

Conclusion: Synthesizing Market Analysis and Future Directions

The recombinant uricase market is experiencing remarkable growth, driven by simultaneous advancements in biotechnology and evolving clinical demands. This comprehensive analysis has highlighted the interplay of product innovations, detailed segmentation insights, and regional market dynamics, offering a panoramic view of the current and emerging trends. As the market continues to evolve, stakeholders are urged to stay ahead by embracing technological innovations and leveraging strategic partnerships that span across research, regulatory, and operational domains. The rigorous review of market segmentation-spanning product types, routes of administration, and application areas-coupled with insightful regional and corporate analyses, sets a clear path to capitalize on emerging opportunities. As this field matures, the synthesis of clinical data with innovative manufacturing processes will further refine the therapeutic landscape, ultimately improving patient outcomes. Decision-makers must navigate these shifting paradigms through a structured approach that integrates rigorous market analysis with proactive strategic investments. In summary, the confluence of research excellence, industry collaboration, and agile market responses is steering the recombinant uricase market towards a robust and sustainable future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of gout and hyperuricemia worldwide
      • 5.1.1.2. Growing awareness of targeted therapies and personalized medicine approaches
      • 5.1.1.3. Expansion of patient population, novel drug formulations, and supportive regulatory frameworks
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of recombinant uricase therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel uricase therapies with improved efficacy and safety profiles
      • 5.1.3.2. Increasing regulatory incentives, including orphan drug status, encouraging innovation
    • 5.1.4. Challenges
      • 5.1.4.1. Potential for adverse reactions and the development of anti-drug antibodies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type : High preference for non-pegylated uricase in acute care settings requiring swift management of complicated gout and hyperuricemia
    • 5.2.2. Application : Significant adoption of gout treatment due to the ongoing need for practical solutions managing elevated uric acid levels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Recombinant Uricase Market, by Product Type

  • 6.1. Introduction
  • 6.2. Biosimilars of Recombinant Uricase
  • 6.3. Non-Pegylated Uricase
  • 6.4. Pegylated Uricase

7. Recombinant Uricase Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Intravenous
  • 7.4. Subcutaneous

8. Recombinant Uricase Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Treatment
  • 8.3. Gout Treatment
    • 8.3.1. Chronic Gout
    • 8.3.2. Hyperuricemia
    • 8.3.3. Refractory Gout
    • 8.3.4. Tumor Lysis Syndrome
  • 8.4. Kidney Diseases
  • 8.5. Neurological Disorders
  • 8.6. Rare Genetic Disorders

9. Recombinant Uricase Market, by End-User

  • 9.1. Introduction
  • 9.2. Healthcare Providers
    • 9.2.1. Clinics
    • 9.2.2. Dialysis Centers
    • 9.2.3. Hospitals
  • 9.3. Pharmaceutical Manufacturers
  • 9.4. Research & Development Institutes

10. Americas Recombinant Uricase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Recombinant Uricase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Recombinant Uricase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Protalix BioTherapeutics receives USD 20 million milestone to fuel pipeline expansion
    • 13.3.2. Protalix BioTherapeutics launches a phase I first-in-human trial evaluating PRX-115
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3SBio Inc.
  • 2. BioCryst Pharmaceuticals, Inc.
  • 3. Biosynth Ltd
  • 4. Creative Enzymes
  • 5. CUSABIO TECHNOLOGY LLC
  • 6. GenScript Biotech Corporation
  • 7. Hzymes Biotech
  • 8. Innovent Biologics, Inc.
  • 9. Kikkoman Corporation
  • 10. Merck KGaA
  • 11. OYC Americas, Inc.
  • 12. Protalix BioTherapeutics
  • 13. Sisco Research Laboratories Pvt. Ltd.
  • 14. Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. RECOMBINANT URICASE MARKET MULTI-CURRENCY
  • FIGURE 2. RECOMBINANT URICASE MARKET MULTI-LANGUAGE
  • FIGURE 3. RECOMBINANT URICASE MARKET RESEARCH PROCESS
  • FIGURE 4. RECOMBINANT URICASE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RECOMBINANT URICASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. RECOMBINANT URICASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. RECOMBINANT URICASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RECOMBINANT URICASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RECOMBINANT URICASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RECOMBINANT URICASE MARKET DYNAMICS
  • TABLE 7. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY BIOSIMILARS OF RECOMBINANT URICASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY NON-PEGYLATED URICASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PEGYLATED URICASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HYPERURICEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY REFRACTORY GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY TUMOR LYSIS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL RECOMBINANT URICASE MARKET SIZE, BY RESEARCH & DEVELOPMENT INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES RECOMBINANT URICASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT URICASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY GOUT TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM RECOMBINANT URICASE MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 284. RECOMBINANT URICASE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 285. RECOMBINANT URICASE MARKET, FPNV POSITIONING MATRIX, 2024